Current Status
Not Enrolled
Get Started


Semaglutide and Type 2 Diabetes

Contact Hours Awarded: 2 , including 1 pharmacology contact hour

Start Course

Course Overview

Semaglutide and Type 2 Diabetes

Author: Maureen Sullivan-Tevault


In 2017, the FDA approved the use of semaglutide injectable (Ozempic) in the treatment of type 2 diabetes. The drug has experienced widespread acceptance due to its positive effects on weight loss and lowering of chronic health risks. The drug has risen in popularity over the past few years, as many well-known actors/actresses/songwriters, and more came forward, publicly sharing their weight loss journey.

This rise in popularity has also resulted in significant shortages of this medication, negatively impacting the lives of the diabetic community, local pharmacies, and healthcare providers. The goal of this continuing education program is to educate and empower the healthcare provider in all aspects of this drug regimen: clinical indications, patient education, cost options, and benefit/risk analysis.

Course Outline

  1. Diabetes Overview
  2. Types of Diabetes
  3. Diagnostic testing to confirm diabetes
  4. Lifestyle Interventions and the Diabetes Prevention Program
  5. Semaglutide (Ozempic)
  6. Antagonist/ Agonist GLP-1, ghrelin and leptin
  7. Semaglutide Overview
    – Side Effects
    – Contradictions
    – Black Box Warning

     Treatment Guidelines
    – Costs
  8. Semaglutide, diabetes and gastroparesis
  9. Lifestyle behavior modification education
  10. Case study

    Accreditation Statement

    Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    In this course, we will discuss the various types of substance abuse and the signs and symptoms of each. It will take the average learner 180 minutes to complete and awards 3 contact hours of continuing education.

    Course Outcomes

    After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

    1. Describe the action of non-insulin injectable diabetes medication semaglutide.
    2. Identify patient-specific contraindications for this medication.
    3. Discuss the long-term use of semaglutide injectables specific to the treatment of type 2 diabetes.

    Target Audience

    • Registered Nurses (RN)
    • Advanced Practice Registered Nurses (APRN)
    • Licensed Practical Nurses (LPN/LVN)

    Requirement for Completion

    1. Enrollment in the course by the learner
    2. Read and learn all course materials
    3. Complete the course evaluation
    4. Attest and testify learning of the course materials

    Accreditations + Approvals

    • American Nurses Credentialing Center (ANCC) (P0614)
    • California Board of Registered Nursing (CEP 17418)
    • Kentucky Board of Nursing (7-0090)
    • Louisiana State Board of Nursing (58)
    • New York State Department of Education (IC 208)
    • Florida Board of Nursing (50-23983)

    Disclosure of Relevant Financial Relationships

    Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.

    Start Course

    Course created on: September 01, 2023

    Course Expires on: September 01, 2026

    Course Offering: #177